# Sarepta/ Roche Duchenne therapy to face new late-stage trial targeting EU nod.

*biotech · news · 2026-04-16 · Seeking Alpha*

## Key points

- Roche is initiating a new Phase 3 trial for Elevidys targeting Duchenne muscular dystrophy.
- The new trial aims specifically to support Elevidys approval in the European Union.
- Elevidys was developed through collaboration between Roche and Sarepta Therapeutics.
- Prior data was insufficient for EU approval, prompting this additional late-stage trial.

**Companies:** Roche, Sarepta Therapeutics
**Countries:** Switzerland, United States

[Read the full story on Seeking Alpha](https://seekingalpha.com/news/4575783-sarepta-roche-duchenne-therapy-face-new-late-stage-trial)

---

Canonical: https://newsio.io/n/12015af0-bf94-48da-a808-15a1b43a9b24/sarepta-roche-duchenne-therapy-to-face-new-late-stage-trial-targeting-eu-nod
Summarized by Newsio from Seeking Alpha. https://newsio.io/how-it-works